Healthcare
Live Price
Offline$44.96
+0.74% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cerevel Therapeutics Holdings, Inc. (CERE) is a Healthcare stock with a market cap of $8.19B. The stock last traded around $44.96. Baseline metrics include revenue growth of 0.0%, EPS growth of -15.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -15.1%, free cash flow -16.5% with operating margin 0.0% and ROIC -38.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CERE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CERE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CERE Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CERE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$128.4M
+15.6% YoY
Free Cash Flow
-$71.8M
+47.5% YoY
Revenue Growth
+0.0%
EPS Growth
-15.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -6M | -5M | -3M | -397K | 0 |
| Operating Income | -447M | -368M | -220M | -149M | -83M |
| EBITDA | -416M | -337M | -212M | -149M | -37M |
| Net Income | -433M | -352M | -222M | -152M | -128M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 991M | 137M | 193M | 384M | 80M |
| Total Assets | 1.2B | 1.0B | 689M | 445M | 121M |
| Total Liabilities | 570M | 497M | 110M | 61M | 43M |
| Shareholder Equity | 674M | 521M | 579M | 385M | 78M |
| Total Debt | 481M | 367M | 37M | 33M | 28M |
| Net Debt | -510M | 230M | -156M | -351M | -51M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
71M
+40.0% YoY
Capital Expenditures
1M
+94.2% YoY
Free Cash Flow
72M
+47.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-72.4%
Debt / Equity
0.71x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.